News | Leads Implantable Devices | September 20, 2019

New Research on Tempo Temporary Pacing Lead to Be Featured at TCT 2019

Multi-center U.S. study demonstrating safety and efficacy of the Tempo Lead also published in Catheterization and Cardiovascular Interventions

New Research on Tempo Temporary Pacing Lead to Be Featured at TCT 2019

September 20, 2019 — BioTrace Medical Inc. announced the company’s key activities at the 31st annual Transcatheter Cardiovascular Therapeutics (TCT) conference, which will take place Sept. 25-29, 2019, in San Francisco.

The company’s Tempo Temporary Pacing Lead will be featured in a breakfast symposium titled “Keeping the Rhythm with the Tempo Lead: Safety, Stability and Ambulation for Transcatheter Aortic Valve Replacement (TAVR) and Other Cardiac Procedures,” which will be chaired by Stanley J. Chetcuti, M.D., director of the cardiac catheterization laboratory at the University of Michigan Health System, and Tamim M. Nazif, M.D., director of clinical services for the Structural Heart & Valve Center at NewYork-Presbyterian/Columbia University Medical Center.

The symposium will feature recent clinical experience from several leading U.S. structural heart centers, highlighting the safety and efficacy of the Tempo Lead, its use in TAVR procedures, and its positive impact on facilitating post-TAVR patient ambulation outside of the ICU and CCU. The session will also provide an opportunity for hands-on demonstrations. 

Nazif will discuss NewYork-Presbyterian/Columbia University Medical Center’s experience using the Tempo Lead during his presentation titled “Conduction Disturbances After TAVR: Current Thinking and Clinical Relevance.” The Tempo Lead will also be utilized during live case broadcasts from NewYork-Presbyterian/Columbia University Medical Center.

Additionally, the company announced the publication of the results of a U.S. multi-center study of 269 cardiac procedures, predominantly TAVR, in Catheterization and Cardiovascular Interventions.[2] The results confirm the Tempo Lead is safe and effective for temporary cardiac pacing, provides stable peri- and post-procedural pacing support, and facilitates post-procedure ambulation.[1] The Tempo lead was successfully positioned and achieved pacing in 264 of 269 patients (98.1 percent). Two patients (0.8 percent) experienced loss of pace capture. Procedural mean pace capture threshold (PCT) was 0.7 ± 0.8 mA. There were no safety events, including perforations, pericardial effusions or sustained device-related arrhythmias. The Tempo lead was left in place post-procedure in 189 patients (71.6 percent) for a mean duration of 43.3 ± 0.7 hours with a final mean PCT of 0.84 ± 1.04 mA. With the Tempo lead in place, 159 of 189 patients (84.1 percent) mobilized from bed to chair at a minimum, and 134 patients (70.8 percent) ambulated without any restrictions related to the pacing lead. There were no lead dislodgments or loss of pace capture events for this group of 189 patients.

The study included procedures performed at six leading U.S. centers: NewYork-Presbyterian/Columbia University Medical Center, University of Michigan Health Center, Riverside Methodist Hospital/OhioHealth, Cleveland Clinic Heart & Vascular Institute, Intermountain Medical Center and Yale New Haven Hospital.

Since receiving FDA clearance, the Tempo Lead has been used in more than 4,500 U.S. procedures, with a safety and performance profile superior to conventional temporary leads, according to BioTrace Medical, including a 0.04 percent cardiac perforation rate and a 0.04 percent dislodgment rate with loss of pace capture.[3]

For more information: www.biotracemedical.com

 

References

1. Nazif T.M., Chen S., Codner P., et al. The initial U.S. experience with the Tempo active fixation temporary pacing lead in structural heart interventions. Catheter Cardiovasc Interv. 2019;1–6. https://doi.org/10.1002/ccd.28476

2. Nazif T.M., Chen S., Codner P., et al. The initial U.S. experience with the Tempo active fixation temporary pacing lead in structural heart interventions. Catheterization and Cardiovascular Interventions, published online Sept. 2, 2019. https://doi.org/10.1002/ccd.28476

3. Company data on file as of September 2019

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...